Literature DB >> 2745305

Operation Everest II: maximal oxygen uptake at extreme altitude.

A Cymerman1, J T Reeves, J R Sutton, P B Rock, B M Groves, M K Malconian, P M Young, P D Wagner, C S Houston.   

Abstract

Chronic exposure to high altitude reduces maximal O2 uptake (VO2max). At extreme altitudes approaching the summit of Mt. Everest [inspiratory PO2(PIO2) = 43 Torr], mean VO2max have been determined to be 15.3 ml.kg-1.min-1 in two subjects who breathed 14% O2 at 6,300 m on Mt. Everest (West et al., J. Appl. Physiol. 54: 1188-1194, 1983). To provide a more complete description of performance near the limits of human tolerance to chronic hypoxia, we measured VO2max in volunteers in an altitude chamber before, during, and after a 40-day decompression to a barometric pressure (PB) of 240 Torr (PIO2 = 43 Torr). In five of eight subjects studied at sea level and PB of 464, 347, 289, and 240 Torr, VO2max was reduced from 4.13 to 1.17 l/min (49.1-15.3 ml.kg-1.min-1) in agreement with the prior study. Although the range decreased, the rank order among the subjects was preserved. Arterial O2 saturation at maximum effort decreased (46% by ear oximetry), but minute ventilation, respiratory frequency, and tidal volume did not. The highest minute ventilation (201 l/min BTPS) was observed at PB of 464 Torr. Arterial PCO2 in three subjects at PB of 240 Torr, at rest, and with maximum effort, averaged 10.3 and 9.6 Torr, respectively. Sustained hyperventilation was crucial to exercise performance during chronic, severe hypoxemia. VO2max was lower after altitude exposure compared with initial sea level values, indicating that exposure had not improved sea level exercise capacity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2745305     DOI: 10.1152/jappl.1989.66.5.2446

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  18 in total

1.  Muscle intracellular oxygenation during exercise: optimization for oxygen transport, metabolism, and adaptive change.

Authors:  Peter D Wagner
Journal:  Eur J Appl Physiol       Date:  2011-04-22       Impact factor: 3.078

Review 2.  Central and peripheral aspects of oxygen transport and adaptations with exercise.

Authors:  P D Wagner
Journal:  Sports Med       Date:  1991-03       Impact factor: 11.136

Review 3.  Acute mountain sickness. Effects and implications for exercise at intermediate altitudes.

Authors:  E C Pigman
Journal:  Sports Med       Date:  1991-08       Impact factor: 11.136

4.  Mountaineering experience decreases the net oxygen cost of climbing Mont Blanc (4,808 m).

Authors:  Veronique L Billat; Maryse Dupré; Jason R Karp; Jean Pierre Koralsztein
Journal:  Eur J Appl Physiol       Date:  2009-12-24       Impact factor: 3.078

Review 5.  Maximal oxygen consumption in healthy humans: theories and facts.

Authors:  Guido Ferretti
Journal:  Eur J Appl Physiol       Date:  2014-07-02       Impact factor: 3.078

Review 6.  Multiple sprint work : physiological responses, mechanisms of fatigue and the influence of aerobic fitness.

Authors:  Mark Glaister
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

7.  The heart and lungs at extreme altitude.

Authors:  J T Reeves; C H Welsh; P D Wagner
Journal:  Thorax       Date:  1994-07       Impact factor: 9.139

8.  The effect of high-altitude on human skeletal muscle energetics: P-MRS results from the Caudwell Xtreme Everest expedition.

Authors:  Lindsay M Edwards; Andrew J Murray; Damian J Tyler; Graham J Kemp; Cameron J Holloway; Peter A Robbins; Stefan Neubauer; Denny Levett; Hugh E Montgomery; Mike P Grocott; Kieran Clarke
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

9.  Arterial hypoxemia and performance during intense exercise.

Authors:  M D Koskolou; D C McKenzie
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1994

10.  Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction.

Authors:  Emidio E Pistilli; Sasha Bogdanovich; Matias Mosqueira; Jennifer Lachey; Jasbir Seehra; Tejvir S Khurana
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-10-28       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.